G01N 2333/50
Fibroblast growth factors [fgf]
Official title: Fibroblast growth factors [FGF]
G01N2333/50 (Fibroblast growth factors [fgf]) appears on 167 US grants and 182 published applications in this corpus.
Search patents in G01N- Granted patents
- 167
- Published applications
- 182
- Assignees
- 116
- Inventors
- 422
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 6 | 0 |
| 1997 | 19 | 0 |
| 1998 | 26 | 0 |
| 1999 | 4 | 0 |
| 2000 | 4 | 0 |
| 2001 | 6 | 0 |
| 2002 | 6 | 9 |
| 2003 | 2 | 8 |
| 2004 | 6 | 9 |
| 2005 | 3 | 8 |
| 2006 | 3 | 3 |
| 2007 | 4 | 4 |
| 2008 | 2 | 8 |
| 2009 | 3 | 13 |
| 2010 | 7 | 8 |
| 2011 | 5 | 4 |
| 2012 | 3 | 6 |
| 2013 | 1 | 5 |
| 2014 | 1 | 9 |
| 2015 | 3 | 13 |
| 2016 | 7 | 11 |
| 2017 | 4 | 10 |
| 2018 | 4 | 10 |
| 2019 | 5 | 4 |
| 2020 | 8 | 11 |
| 2021 | 4 | 6 |
| 2022 | 5 | 5 |
| 2023 | 1 | 3 |
| 2024 | 2 | 5 |
| 2025 | 3 | 6 |
| 2026 | 3 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- FGF21 responsive reporter gene cell line27 Jan 2026US 12,534,502 B2Svar Life Science AB
- Mutant fibroblast growth factor 21 (FGF21) polypeptides27 Jan 2026US 12,534,503 B2Yale University
- Biomarkers for risk prediction of mortality6 Jan 2026US 12,517,139 B2Roche Diagnostics Operations, Inc.
- Biomarkers for a therapy comprising a sorafenib compound23 Dec 2025US 12,504,431 B2Eisai R&D Management Co., Ltd.
- Measurement method for fibroblast growth factor-23 by forming immunocomplexes16 Dec 2025US 12,498,366 B2Canon Medical Diagnostics Corporation
- Human anti-fgf2 monoclonal antibody (mab), pharmaceutical composition comprising same, use thereof and kit for the detection of cancer in a biological sample comprising said mab1 Oct 2026US 2026/0297170 A1Instituto Butantan
- Sarcopenia treatment effect through inhibition of fgf18 signaling pathway16 Jul 2026US 2026/0199345 A1Knu-Industry Cooperation Foundation
- Combination drug21 May 2026US 2026/0140118 A1Chugai Seiyaku Kabushiki Kaisha
- Biomarker compositions, protein panels, devices, and methods to identify risk of and treat pulmonary vascular inadequacy in single ventricle heart disease5 Mar 2026US 2026/0063645 A1The Regents of the University of Colorado, a body corporate
- Tropnin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction27 Nov 2025US 2025/0362308 A1Roche Diagnostics Operations, Inc.
Most cited
By later US patents
- Nucleic acid ligands561US 5,475,096 AUniversity Research Corporation · 1995
- Systematic evolution of ligands by exponential enrichment: chimeric selex281US 5,637,459 ANeXstar Pharmaceuticals, Inc. · 1997
- High affinity nucleic acid ligands containing modified nucleotides228US 5,660,985 ANeXstar Pharmaceuticals, Inc. · 1997
- Methods of producing nucleic acid ligands204US 5,595,877 ANeXstar Pharmaceuticals, Inc. · 1997
- High affinity nucleic acid ligands containing modified nucleotides190US 5,958,691 ANeXstar Pharmaceuticals, Inc. · 1999